Background: The aim of the present study was to assess the longitudinal accumulation of diabetes-related complications and the effect of glycemic control on the Diabetes Complications Severity Index (DCSI) score in people with newly diagnosed type 2 diabetes (T2D). Methods: A retrospective cohort study was conducted using electronic health records from a large integrated healthcare system. People with newly diagnosed T2D were identified between 2005 and 2016 and stratified by initial HbA1c category (<7%, <8%, ≥8%). The DCSI scores were determined for each study year, and the cumulative incidence of diabetes-related complications was assessed. A Cox proportional hazard model was used to evaluate the effect of baseline HbA1c and worsening glycemic (HbA1c) control on longitudinal changes in DCSI scores. Results: Of 32 174 people identified as having newly diagnosed T2D, 14 016 (44%), 21 657 (67%), and 9983 (31%) had an initial or baseline HbA1c <7%, <8%, and ≥8%, respectively. Ten years after diabetes diagnosis, retinopathy, chronic kidney disease, coronary heart disease, and neuropathy were diagnosed in 22%, 29%, 24%, and 36% of people. Baseline HbA1c did not affect the observed trend in longitudinal changes in DCSI scores throughout the 11-year period. For people in each of the initial HbA1c groups (<7%, <8%, ≥8%), worsening or persistently poor glycemic control was significantly associated with a 10%, 19%, or 16% increase in the risk of experiencing an increased DCSI score, respectively (all P < 0.01).
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Introduction
The landmark UK Prospective Diabetes Study (UKPDS) 1 evaluated the effect of intensive glycemic control compared with conventional treatment on the risk of developing complications in a population of people with newly diagnosed type 2 diabetes (T2D). Although intensive glycemic control was found to be associated with a lower risk of developing or worsening diabetes-related complications, especially microvascular complications, the prevalence of microvascular complications was noted to be rather high at baseline: retinopathy 36%, nephropathy (proteinuria) 1.9%, and neuropathy 11.5%. 1 This observation suggests that people likely had diabetes for many years prior to the formal recognition and diagnosis. Indeed, it has been estimated that people in the UKPDS had T2D for at least 4 years prior to the formal diagnosis. 2, 3 Accordingly, the UKPDS appears to have identified a population of people with newly diagnosed T2D, not a newonset population. Identifying people with T2D prior to the onset of symptoms and formal presentation to their healthcare provider has proven to be challenging. However, with the advent of electronic health records (EHRs) and the rich laboratory and clinical data they contain, it may be possible to identify people closer to the time of disease onset and assess the development of complications over time. The Diabetes Complications Severity Index (DCSI), a 13-point scale scored from patient medical record data, was developed to quantify the severity of complications and to potentially better predict the risk of adverse outcomes in people with diabetes. 4 Each level of the continuous DCSI was found to be associated with a 1.34-fold greater risk of death, with similar results observed for the association of the DCSI with risk of hospitalization. The DCSI was also found to be a slightly better predictor of mortality than a simple count of the number of complications. 4 Given these findings, it would appear that the DCSI, and how that score changes continuously over time, would be a meaningful clinical parameter for clinicians to calculate and monitor using available EHR data.
The medical literature lacks real-world evidence regarding how the DCSI of people with newly diagnosed T2D changes over time. In addition, it remains unclear whether the level of glycemic control at the time of diagnosis affects the progression of the DCSI, or how worsening or persistently poor glycemic control over time may affect the DCSI in a longitudinal manner. The aims of the present study were to describe documentation of diabetes complications in EHRs, to evaluate how the DCSI changes in a longitudinal manner in people with newly diagnosed T2D managed within a large integrated delivery system, and to determine what effect, if any, baseline HbA1c and changes in HbA1c have on the DCSI. This would seem important given that the DCSI has been found to both predict mortality and the risk of hospitalization for people with diabetes. 4 Determining how the DCSI changes longitudinally in people with newly diagnosed T2D, and how glycemic control affects the DCSI, could potentially help clinicians identify high-risk people sooner, allowing for a more timely and aggressive intervention to take place, which may reduce the long-term risk of adverse outcomes.
Methods
The present study was a retrospective cohort study using T2D incidence cases seen at the Cleveland Clinic between 2005 and 2016. Incidence cases of T2D were identified using a modified version 5 of the eMERGE algorithm developed by Kho et al. 6 The algorithm calculates the earliest date of when a patient record contains one of the following ("incident event"): a T2D International Classification of Diseases (ICD) code and a T2D medication; a T2D code and abnormal glucose; two T2D codes and an outpatient insulin order; a T2D medication and abnormal glucose; or insulin preceded by T2D medication. To identify incidence cases of T2D, the patient had to have two encounters with a primary care provider or endocrinologist without any indication (laboratory values, diagnosis codes etc.) of a T2D diagnosis within the EHR prior to the incident event. All people with ICD-9 codes of 250.x0 (Diabetes mellitus type 2) or 250.x2 (Diabetes mellitus type 2, uncontrolled) were used within the modified eMERGE algorithm, except for ICD-9 codes 250.10 and 250.12, because these are indicative of T2D with ketoacidosis, a condition that more closely resembles type 1 diabetes (T1D). People with an ICD-9 code specific for T1D (250.x1, 250.x3) at any time were excluded from the cohort. The DCSI score was calculated via the methods described by Young et al. 4 using ICD-9 codes and creatinine values contained within the EHR. The DCSI was calculated on the date of T2D diagnosis (baseline) and recalculated at the end of each calendar year of the study time frame until the patient was no longer being followed-up or was lost to follow-up.
The rate of developing chronic kidney disease (CKD), retinopathy, coronary heart disease (CHD), and neuropathy, without stratifying by initial HbA1c (closest recorded value to baseline), was determined, where each individual DCSI comorbidity or complication was calculated at T2D diagnosis and followed; the rate was recorded at the end of each year and at baseline T2D diagnosis plus 90 days. Chronic kidney disease, CHD, neuropathy, and retinopathy were identified by the presence of relevant ICD-9 codes occurring in any of the structured areas of the EHR (problem list, past medical history, inpatient diagnoses, and encounter diagnoses). In addition, CKD was identified based on an estimated glomerular filtration rate (eGFR) <60 mL/min, calculated via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, 7, 8 using outpatient serum creatinine values. People with two eGFR values <60 mL/min at least 90 days apart, with no normal eGFR values in between, were considered to have CKD.
If a patient had no EHR data for a period of ≥1 year, data for the year preceding the gap year(s) were carried forward until the next year with data, based on the assumption that because the patient had not been seen in the interim, no new complications had developed.
Statistical analysis
The relationship between DCSI and glycemic control (HbA1c) was evaluated using a stratified analysis based on HbA1c level categories, an approach considered by the authors to provide a more accurate risk assessment than a single model. The cohort was divided into three groups depending on the initial HbA1c level, as follows: <7% (<53 mmol/mol), <8% (<64 mmol/mol), and ≥8% (≥64 mmol/mol; hereafter, HbA1c levels are designated by percentage values only). Three separate Cox proportional regression models were developed between DCSI scores and HbA1c for the three strata, in which HbA1c was used as a time-dependent covariate instead of a fixed-effect covariate to capture the effect of time on the covariate. A linear regression model with a fixed-effect treatment of HbA1c would have failed to incorporate the time effect in risk assessment in the model, but this could be achieved using a Cox regression model. Because one person can experience multiple changes in their DCSI score, we used the counting process formulation of Andersen and Gill, 9 where HbA1c control was modeled as a time-dependent covariate and both the DCSI score and HbA1c control variables used a start and stop interval format for the model. For example, each person was followed until they had a change in HbA1c value that moved them into a different HbA1c category (e.g. from HbA1c <7% to HbA1c <8%). At that point, time was stopped in the model and then restarted with the person's new HbA1c control information. Changes in DCSI score were dealt with similarly. People were censored when deceased or lost to followup. To account for the potential correlation within repeated measures of individuals, a cluster variance was added to the model. All analyses were performed using R statistical software (R Core Team for Statistical Computing, Vienna Austria). This study was approved by the Cleveland Clinic's Institutional Review Board.
Results

Baseline characteristics stratified by baseline HbA1c category
There were 32 174 people identified as having newly diagnosed T2D within the EHR between 2005 and 2016; 14 016 (44%) had an initial/baseline HbA1c <7%, 21 657 (67%) had an initial HbA1c <8%, 9983 (31%) had an initial HbA1c ≥8%, and 2% had a missing HbA1c value at baseline ( categories of <7% and <8% had slightly higher percentages of women (54% and 53%, respectively), whereas a higher percentage of men was observed in the baseline HbA1c category ≥8% (55% men). A higher percentage of Black people was observed in the baseline HbA1c category ≥8% (23%) compared with the baseline HbA1c <7% and <8% groups (both 18%). Smaller proportions of people with CHD and cerebral vascular accident (CVA) were observed in the baseline HbA1c category ≥8% compared with the lower HbA1c categories. Similar percentages of heart failure were observed across the baseline HbA1c categories. The overall baseline rates of CKD, retinopathy, CHD, and neuropathy, not stratified by baseline HbA1c, were 2%, 1%, 2%, and 2%, respectively ( Table 2) .
Accumulation of select comorbidities
The accumulation of primary diabetes outcomes (CKD, retinopathy, CHD, and neuropathy) for each year after the diagnosis of T2D is presented in Table 2 . In addition, Fig. 1a shows the cumulative incidence of developing CKD, retinopathy, CHD, and neuropathy over time.
Change in DCSI score over time, stratified by baseline HbA1c category Table 3 presents the categorical distribution of DCSI scores at each point in time (each year) after the date of T2D diagnosis, stratified by baseline HbA1c. The DCSI trends appear to be similar, regardless of baseline HbA1c, in terms of score distributions throughout the 10-year period, with very similar distributions of DCSI scores at the 10-year mark within each HbA1c category. Changes in mean DCSI scores over time, stratified by baseline HbA1c category, are shown in Fig. 1b .
Relationship between HbA1c control and risk of DCSI score increase
Within all three cohorts (initial HbA1c <7%, <8%, and ≥8%), poor or worsening glycemic control was found to be significantly associated with an increase in a person's DCSI score (Table 4) . For people with a baseline HbA1c <7% and <8%, worsening glycemic control, defined as an increase in HbA1c above the baseline category, was associated with a 10% and 19% increase in the risk of experiencing an increase in the DCSI score, respectively (P < 0.01). In the case of people with a baseline HbA1c ≥8%, persistently poor glycemic control (≥8%) was found to be associated with a 16% increase in the risk of experiencing an increase in the DCSI score (P < 0.01). *The number of people at risk is the number of people with follow-up data through the given year, excluding people who had died, were lost to follow-up, or had previously experienced the event of interest.
Discussion
In this analysis, there did not appear to be an association between baseline glycemic control and longitudinal changes in DCSI score. However, an association between worsening or persistently poor glycemic control during the follow-up period was found to be significantly associated with an increase in DCSI scores over time, across all baseline HbA1c categories. The DCSI has been found to be a better predictor of mortality than a simple count of the number of complications, 4 and each level of the continuous DCSI has been reported to be associated with a 1.34-fold greater risk of death (with similar results observed for the association of DCSI with risk of hospitalization). 4 Thus, determining how the DCSI score changes in a longitudinal manner, and what effect glycemic control has on those changes, would seem important in the care of people with T2D. To our knowledge, the present study is the first report to evaluate associations between baseline glycemia and changes in glycemic control on the DCSI in a longitudinal manner.
The DCSI score would seem to be a useful parameter to follow given its ability to predict mortality and/or hospitalizations, 4 yet it remains underused in the clinical setting, possibly because clinicians have not wanted to be burdened with calculating the score. However, with the advent of EHR technology, this task can be performed with far less time and effort. Calculating and monitoring the DCSI score in a longitudinal manner could potentially assist clinicians in identifying people at higher risk of developing complications, allowing for a more timely intervention, ideally prior to the development of an adverse outcome.
Although our observation that worsening glycemic control was significantly associated with an increased risk of a person experiencing a worsening DCSI score was not unexpected, the magnitude of the observed increase in risk was not as significant as anticipated. The reasons for this are likely multifactorial. Our definition of worsening glycemic control was categorical (i.e. an HbA1c above the respective baseline HbA1c category) and may not have been of sufficient magnitude to truly evaluate the effect of worsening glycemic control on the risk of developing complications or experiencing an increase in DCSI score. It is also possible that HbA1c may simply not be the best outcome marker for diabetes studies, the best reflection of glycemic control, or the largest driver of the development of complications. 10, 11 It has long been perceived that the risk of developing diabetes-related complications or adverse outcomes could be reduced by reaching goal HbA1c values, historically defined as an HbA1c <7%. However, glycemic control implications, and the specific markers to be used for defining glycemic control, have become hot topics of debate in recent years; studies have suggested that glycemic variability may be a more important driver of the development of complications, rather than just "average glycemic control" as defined by the HbA1c. 10, 11 Emerging study data suggest that the means by which glycemic control is achieved may also affect the development of complications and the risk of adverse cardiovascular outcomes. For example, recent studies with empagliflozin (a sodium-glucose cotransporter 2 inhibitor) and the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide noted a reduction in cardiovascular risk compared with placebo or control groups, despite the fact that the differences in glycemic control (HbA1c) in the active versus comparator groups were ≤1% across all three trials. [12] [13] [14] In contrast, the dipeptidyl peptidase 4 inhibitors were not found to be associated with a reduction in cardiovascular risk, although they did demonstrate cardiovascular safety, the primary intent of the trials. [15] [16] [17] Differences in the risk of microvascular complications have also been reported; in the liraglutide cardiovascular safety trial, nephropathy events were lower in the liraglutide than placebo group (1.5 vs 1.9 events per 100 person-years of observation, respectively). 13 In the semaglutide cardiovascular outcome trial, the rates of new or worsening nephropathy were lower in the semaglutide group, but rates of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) were significantly higher (hazard ratio 1.76; 95% confidence interval 1.11-2.78; P = 0.02).
14 These observations highlight that there are other variables beyond glycemic control (i.e. choice of treatment) that can affect the risk of developing complications. In the present cohort of people with newly diagnosed T2D, we did not assess the longitudinal effect of antidiabetic therapies on the DCSI score, but this would seem to be an important topic for future investigation.
One strength of the present study is that the data were derived from the enterprise-wide EHR at Cleveland Clinic, which contains rich clinical patient data, allowing for the accurate capture of comorbidities and diabetes-related complications and subsequent calculation of DCSI scores. The study also included up to 11 years of follow-up, which afforded a robust longitudinal assessment of the accrual of comorbidities, complications, and changes in DCSI scores. Despite these strengths, the present study is not without limitations. First, HbA1c data were not available for all people at all time points and some people were lost to follow-up; thus, only a subset (23%) had 11 years of follow-up information. In addition, we were unable to evaluate the effects of other variables, such as glycemic variability or antidiabetic therapies, on the longitudinal changes in DCSI scores. Given the duration of followup, and the observation that people switch from one class of drug to another, or have additional antidiabetic medications added to their baseline regimen in a longitudinal manner, evaluating the effect of the therapeutic choices on the DCSI score was not possible. There is also considerable discrepancy between the prevalence of complications at baseline in the present study compared with that described by the UKPDS. 1 The reason for this is likely to be multifactorial, with the most important being that different definitions of complications and different means of recognizing them were used in these studies (we largely relied upon clinician documentation of complications via ICD-9 codes as part of routine medical care, whereas the UKPDS involved prospective and purposeful screening for T2D complications). It is possible that the low prevalence of complications at baseline in the present study was because our methodology allowed for the identification of people with T2D truly closer to the onset of the disease, or (more likely) because our data capture was dependent on clinician documentation practices. It is also possible that the observed rates of developing complications in the present study may not truly reflect "real" increases; rather, these increases may reflect, at least in part, improved documentation using EHR technology, especially over the past 5 years, during which time the current healthcare environment has been very focused on more accurate documentation and coding.
Further studies evaluating how the DCSI changes longitudinally in the population of people with newly diagnosed T2D (as well as in those with longstanding T2D), and how the various markers of glycemic control, different antidiabetic therapies, and the management of other comorbidities (e.g. hypertension, hyperlipidemia, obesity) affects the DCSI appear warranted. These studies may help clinicians identify highrisk T2D cases earlier in the disease course, allowing for timelier interventions to take place, which may help reduce the risk of adverse outcomes.
